| abstract |
The invention concerns the use of cysteine derivatives for preparing a medicine for treating diseases resulting from the formation of heterotrimeric G protein. Said diseases include in particular diseases related to biological functions or the following disorders: smell, taste, light perception, neurotransmission, neurodegeneration, functioning of endocrine and exocrine glands, autocrine and paracrine regulation, blood pressure, embryogenesis, benign cell proliferation, oncogenesis, viral infection, immunological functions, diabetes, obesity, benign and malign proliferative diseases. Said cystein derivatives comprise in particular: bis-1,1'-[7-(2-amino-1-oxo-3-thiopropyl)-8-(cyclohexylmethyl)-2-(2-methoxyphenyl)-5,6,7,8-tetrahydroimidazol[1,2a]pyrazine (I) disulphide; and bis-1,1'-7- (2-amino- 1-oxo-thiopropyl- (2-(1-naphthyl)-8- (2-methylpropyl)- 5,6,7,8- tetrahydroimidazol [1,2a]pyrazin-7-yl) disulphide (II). |